IgA Nephropathie - Prof. Dr. Jürgen Floege (Aachen)

Herr Prof. Dr. Jürgen Floege (Aachen), Work Group Co-Chair der KDIGO-Leitlinie Glomerulonephritis 2021 und Past Präsident der Deutschen Gesellschaft für Nephrologie, disktuiert etablierte und innovative Therapieoptionen für die IgA-Nephropathie. Das Gespräch wurde am 13.02.2024 geführt. Moderatoren: Prof. Dr. Andreas Kronbichler (Innsbruck), Dr. Philipp Gauckler (Innsbruck) und Prof. Dr. Gunnar Heine (Frankfurt am Main). Weitere Literatur: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Fellström BC et al.; NEFIGAN Trial Investigators. Lancet 2017 doi: 10.1016/S0140-6736(17)30550-0 Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. Hou FF et al.; MAIN Trial Investigators JAMA Netw Open 2023 doi: 10.1001/jamanetworkopen.2022.54054 A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. Mathur M et al.; ENVISION Trial Investigators Group N Engl J Med 2024 doi: 10.1056/NEJMoa2305635 Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase? Floege J Am J Kidney Dis 2019 doi: 10.1053/j.ajkd.2019.02.022 Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Liu LJ et al. Am J Kidney Dis 2019 doi: 10.1053/j.ajkd.2019.01.026 Supramaximal dose of candesartan in proteinuric renal disease. Burgess E et al.; SMART (Supra Maximal Atacand Renal Trial) Investigators. J Am Soc Nephrol 2009 doi: 10.1681/ASN.2008040416 Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Wimbury D et al. Kidney Int 2024 doi: 10.1016/j.kint.2023.11.003 Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. Pozzi C et al. J Am Soc Nephrol 2004 doi: 10.1097/01.asn.0000103869.08096.4f Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Li PK et al. Am J Med 2013 doi: 10.1016/j.amjmed.2012.06.028 Long-Term Outcomes in IgA Nephropathy. Pitcher D et al. Clin J Am Soc Nephrol 2023 doi: 10.2215/CJN.0000000000000135 Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Barratt J et al.; NefIgArd Trial Investigators Kidney Int 2023 doi: 10.1016/j.kint.2022.09.017 Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Lv J et al.; TESTING Study Group JAMA 2022 doi: 10.1001/jama.2022.5368 A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Wheeler DC et al.; DAPA-CKD Trial Committees and Investigators. Kidney Int 2021 doi: 10.1016/j.kint.2021.03.033 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group Kidney Int 2021 doi: 10.1016/j.kint.2021.05.021 SGLT-2 inhibition in IgA nephropathy: the new standard of care? Barratt J, Floege J. Kidney Int 2021 doi: 10.1016/j.kint.2021.04.002 Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lafayette R et al.; NefIgArd trial investigators Lancet 2023 doi: 10.1016/S0140-6736(23)01554-4 Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium Lancet 2022 doi: 10.1016/S0140-6736(22)02074-8